Quest Diagnostics Incorporated

NYSE:DGX

Market Cap

USD 18.58 B

Share Price

USD 166.45

Avg Daily Volume

1,146,698

Change (1 day)

-0.28%

Change (1 year)

14.00%

Change (YTD)

10.33%

Quest Diagnostics Incorporated EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2025: 19.22%

Quest Diagnostics Incorporated EBITDA Margin is 19.22% for the Trailing 12 Months (TTM) ending March 31, 2025, a 2.45% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Quest Diagnostics Incorporated EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 18.76%, a 9.57% change year over year.
  • Quest Diagnostics Incorporated EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was 17.12%, a -38.84% change year over year.
  • Quest Diagnostics Incorporated EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was 27.99%, a -1.31% change year over year.
  • Quest Diagnostics Incorporated EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was 28.36%, a 45.94% change year over year.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin